Real-world walking speed as a digital biomarker and outcome measure for clinical trials—a systematic review, regulatory status and future directions - 2026
[fr] Introduction
Walking speed is a key measure of health and mobility across a wide range of diseases. Traditional gait assessments in clinical settings may not accurately reflect real-world mobility patterns. Wearable sensors offer an ecologically valid alternative by capturing every movement in daily life, but there are few robust, validated reports. We aimed to identify evidence on real-world gait speed measurements that have received or are seeking regulatory approval from agencies such as the European Medicines Agency and the U.S. Food and Drug Administration.
Method
We conducted a systematic review following a comprehensive search strategy using the Ovid platform, guided by pre-defined selection criteria and in accordance with the Preferred Reporting Items for Systematic Reviews and Meta-Analyses statement. We also manually searched the websites of key regulatory agencies and the ClinicalTrials.gov database.
Results
Our search identified 503 records, of which 10 met the inclusion criteria. Most studies were part of large-scale initiatives, including the qualification of the Stride Velocity 95th Centile and the MOBILISE-D project. No device or outcome measure that assesses walking speed in real-world conditions has been fully validated by the FDA. We found four letters of intent on the FDA website related to this concept. One outcome, the 95th centile of stride velocity, has been approved by the EMA as a primary endpoint for assessing ambulant patients with Duchenne Muscular Dystrophy.
Conclusion
Despite the potential of wearable devices to enhance drug development and clinical decision-making, real-world walking speed remains insufficiently validated across most conditions because data is missing. The widespread adoption of digital outcomes to assess ambulation will require extensive validation efforts, regulatory pathway adaptations, and improved standardization of devices, algorithms, and study methodologies.
Systematic Review Registration
https://www.crd.york.ac.uk/PROSPERO/view/CRD42025633578
, PROSPERO CRD42025633578.
Disciplines :
Neurology
Author, co-author :
Poleur, Margaux ; Université de Liège - ULiège > Département des sciences cliniques ; University Department of Neurology, Citadelle Hospital
Tychon, Cyril ; Université de Liège - ULiège > Faculté de Médecine > Master spéc. pédia.
Gilbert, Stephen; Else Kröner Fresenius Center for Digital Health, TUD Dresden University of Technology ; Faculty of Business and Economics, TUD Dresden University of Technology
Daumer, Martin ✱; SLCMSR E.V. - The Human Motion Institute
Servais, Laurent ✱; Université de Liège - ULiège > Département des sciences cliniques ; Department of Paediatrics, MDUK Oxford Neuromuscular Centre, University of Oxford
✱ These authors have contributed equally to this work.
Language :
French
Title :
Real-world walking speed as a digital biomarker and outcome measure for clinical trials—a systematic review, regulatory status and future directions
Park J Kim T-H. The effects of balance and gait function on quality of life of stroke patients. NeuroRehabilitation. (2019) 44:37–41. 10.3233/NRE-18246730741699
Mirelman A Shema S Maidan I Hausdorff JM. Gait. Handb Clin Neurol. (2018) 159:119–34. 10.1016/B978-0-444-63916-5.00007-030482309
Fischer JS Rudick RA Cutter GR Reingold SC. The multiple sclerosis functional composite measure (MSFC): an integrated approach to MS clinical outcome assessment. Mult Scler. (1999) 5:244–50. 10.1177/13524585990050040910467383
Mcdonald CM Henricson EK Abresch RT Florence J Eagle M Gappmaier E et al. The 6-minute walk test and other clinical endpoints in duchenne muscular dystrophy: reliability, concurrent validity, and minimal clinically important differences from a multicenter study. Muscle Nerve. (2013) 48:357–68. 10.1002/mus.2390523674289
Crapo RO Casaburi R Coates AL Enright PL MacIntyre NR McKay RT et al. ATS Statement: guidelines for the six-minute walk test. Am J Respir Crit Care Med. (2002) 166:111–7. 10.1164/ajrccm.166.1.at110212091180
Shulman LM Gruber-Baldini AL Anderson KE Vaughan CG Reich SG Fishman PS et al. The evolution of disability in Parkinson disease. Mov Disord. (2008) 23:790–6. 10.1002/mds.2187918361474
Fuentes-Abolafio IJ Stubbs B Pérez-Belmonte LM Bernal-López MR Gómez-Huelgas R Cuesta-Vargas AI. Physical functional performance and prognosis in patients with heart failure: a systematic review and meta-analysis. BMC Cardiovasc Disord. (2020) 20:512. 10.1186/s12872-020-01725-533297975
Tasseel-Ponche S Delafontaine A Godefroy O Yelnik AP Doutrellot P-L Duchossoy C et al. Walking speed at the acute and subacute stroke stage: a descriptive meta-analysis. Front Neurol. (2022) 13:989622. 10.3389/fneur.2022.98962236226075
Rosmaninho I Ribeirinho-Soares P Nunes JPL. Walking speed and mortality: an updated systematic review. South Med J. (2021) 114:697–702. 10.14423/SMJ.000000000000131834729613
Liu Y Xu L Xu Y Chen T Zhu G Chen Y. Dose-response association between walking speed and all-cause mortality: a systematic review and meta-analysis of cohort studies. J Sports Sci. (2024) 42:1313–22. 10.1080/02640414.2024.239030239133765
Hackett RA Davies-Kershaw H Cadar D Orrell M Steptoe A. Walking speed, cognitive function, and dementia risk in the English longitudinal study of ageing. J Am Geriatr Soc. (2018) 66:1670–5. 10.1111/jgs.1531229508385
van Munster CEP Uitdehaag BMJ. Outcome measures in clinical trials for multiple sclerosis. CNS Drugs. (2017) 31:217–36. 10.1007/s40263-017-0412-528185158
Kishnani PS Diaz-Manera J Toscano A Clemens PR Ladha S Berger KI et al. Efficacy and safety of avalglucosidase alfa in patients with late-onset pompe disease after 97 weeks: a phase 3 randomized clinical trial. JAMA Neurol. (2023) 80:558–67. 10.1001/jamaneurol.2023.055237036722
Moreau C Rouaud T Grabli D Benatru I Remy P Marques A-R et al. Overview on wearable sensors for the management of Parkinson’s disease. NPJ Parkinsons Dis. (2023) 9:153. 10.1038/s41531-023-00585-y37919332
Poleur M Markati T Servais L. The use of digital outcome measures in clinical trials in rare neurological diseases: a systematic literature review. Orphanet J Rare Dis. (2023) 18:224. 10.1186/s13023-023-02813-337533072
Woelfle T Bourguignon L Lorscheider J Kappos L Naegelin Y Jutzeler CR. Wearable sensor technologies to assess motor functions in people with multiple sclerosis: systematic scoping review and perspective. J Med Internet Res. (2023) 25:e44428. 10.2196/4442837498655
Bakker JP Izmailova ES Clement A Hoffmann S Leptak C Menetski JP et al. Regulatory pathways for qualification and acceptance of digital health technology-derived clinical trial endpoints: considerations for sponsors. Clin Pharmacol Ther. (2025) 117:56–72. 10.1002/cpt.339839148198
Liberati A Altman DG Tetzlaff J Mulrow C Gøtzsche PC Ioannidis JP et al. The PRISMA statement for reporting systematic reviews and meta-analyses of studies that evaluate healthcare interventions: explanation and elaboration. Br Med J. (2009) 339:b2700. 10.1136/bmj.b2700
Düking P Fuss FK Holmberg H-C Sperlich B. Recommendations for assessment of the reliability, sensitivity, and validity of data provided by wearable sensors designed for monitoring physical activity. JMIR Mhealth Uhealth. (2018) 6:e102. 10.2196/mhealth.9341
Food and Drug Administration. FDA Clinical Outcome Assessments : qualification program submissions (n.d.). Available online at: https://www.fda.gov/drugs/clinical-outcome-assessment-coa-qualification-program/clinical-outcome-assessments-coa-qualification-program-submissions (Accessed September 15, 2025a).
European Medicines Agency. EMA qualification opinion for SV95C as primary endpoint in studies in ambulatory Duchenne Muscular Dystrophy studies (n.d.). Available online at: https://www.ema.europa.eu/en/documents/scientific-guideline/qualification-opinion-stride-velocity-95th-centile-primary-endpoint-studies-ambulatory-duchenne-muscular-dystrophy-studies_en.pdf (Accessed September 15, 2025b).
Servais L Eggenspieler D Poleur M Grelet M Muntoni F Strijbos P et al. First regulatory qualification of a digital primary endpoint to measure treatment efficacy in DMD. Nat Med. (2023) 29:2391–2. 10.1038/s41591-023-02459-537814063
Servais L Strijbos P Poleur M Mirea A Butoianu N Sansone VA et al. Evidentiary basis of the first regulatory qualification of a digital primary efficacy endpoint. Sci Rep. (2024) 14:29681. 10.1038/s41598-024-80177-939613806
European Medicines Agency. Briefing Book for the EMA Qualification of novel methodologies for drug development (n.d.). Available online at: https://www.fda.gov/media/124847/download?attachment,%2012%20Dec%202016 (Accessed September 15, 2025a).
Linking digital assessment of mobility to clinical endpoints to drive regulatory acceptance and clinical practice (). Available online at: https://humanmotioninstitute.de/documents/nkWT1Ll8WwYxbYdFPZkaWEDWdsJ9utX8FfS5tpLJ.pdf (Accessed September 15, 2025).
Kirk C Zia Ur Rehman R Galna B Alcock L Ranciati S Palmerini L et al. Can digital mobility assessment enhance the clinical assessment of disease severity in Parkinson’s disease? J Parkinsons Dis. (2023) 13:1001–11. 10.3233/JPD-230044
Poleur M Ulinici A Daron A Schneider O Farra F Demonceau M et al. Normative data on spontaneous stride velocity, stride length, and walking activity in a non-controlled environment. Orphanet J Rare Dis. (2021) 16(1):318. 10.21203/rs.3.rs-178075/v134281599
Haberkamp M Moseley J Athanasiou D de Andres-Trelles F Elferink A Rosa MM et al. European Regulators’ views on a wearable-derived performance measurement of ambulation for duchenne muscular dystrophy regulatory trials. Neuromuscul Disord. (2019) 29:514–6. 10.1016/j.nmd.2019.06.00331272741
Mueller A Hoefling HA Muaremi A Praestgaard J Walsh LC Bunte O et al. Continuous digital monitoring of walking speed in frail elderly patients: noninterventional validation study and longitudinal clinical trial. JMIR Mhealth Uhealth. (2019) 7:e15191. 10.2196/1519131774406
European Medicines Agency. EMA’s Guideline on the Clinical Development of Medicinal Products Intended for the Treatment of Pain (n.d.). Available online at: https://www.ema.europa.eu/en/documents/scientific-guideline/guideline-clinical-development-medicinal-products-intended-treatment-pain-first-version_en.pdf (Accessed September 15, 2025c).
Keppler AM Nuritidinow T Mueller A Hoefling H Schieker M Clay I et al. Validity of accelerometry in step detection and gait speed measurement in orthogeriatric patients. PLoS One. (2019) 14:e0221732. 10.1371/journal.pone.022173231469864
Motl RW Weikert M Suh Y Sosnoff JJ Pula J Soaz C et al. Accuracy of the actibelt® accelerometer for measuring walking speed in a controlled environment among persons with multiple sclerosis. Gait Posture. (2012) 35:192–6. 10.1016/j.gaitpost.2011.09.00521945386
Food and Drug Administration. Letter of intent regarding the use of Actibelt in multiple sclerosis (n.d.).
Pahwa R Isaacson SH Torres-Russotto D Nahab FB Lynch PM Kotschet KE. Role of the personal KinetiGraph in the routine clinical assessment of Parkinson’s disease: recommendations from an expert panel. Expert Rev Neurother. (2018) 18:669–80. 10.1080/14737175.2018.150394830032695
Wiedmann I Grassi M Duran I Lavrador R Alberg E Daumer M et al. Accelerometric gait analysis devices in children—will they accept them? Results from the AVAPed study. Front Pediatr. (2020) 8:574443. 10.3389/fped.2020.57444333585360
European Commission’s platform for Community Research and Development Information Service (n.d.). Available online at: https://cordis.europa.eu/project/id/820820 (Accessed September 15, 2025).
Mikolaizak AS Rochester L Maetzler W Sharrack B Demeyer H Mazzà C et al. Connecting real-world digital mobility assessment to clinical outcomes for regulatory and clinical endorsement–the mobilise-D study protocol. PLoS One. (2022) 17:e0269615. 10.1371/journal.pone.026961536201476
Block VJ Lizée A Crabtree-Hartman E Bevan CJ Graves JS Bove R et al. Continuous daily assessment of multiple sclerosis disability using remote step count monitoring. J Neurol. (2017) 264:316–26. 10.1007/s00415-016-8334-627896433
Watanabe D Yoshida T Watanabe Y Yamada Y Miyachi M Kimura M. Association of the interaction between daily step counts and frailty with disability in older adults. Geroscience. (2024) 47(3):3377–90. 10.1007/s11357-024-01471-y39708216
Espay AJ Hausdorff JM Sánchez-Ferro Á Klucken J Merola A Bonato P et al. A roadmap for implementation of patient-centered digital outcome measures in Parkinson’s disease obtained using mobile health technologies. Mov Disord. (2019) 34:657–63. 10.1002/mds.2767130901495
Goldsack JC Coravos A Bakker JP Bent B Dowling AV Fitzer-Attas C et al. Verification, analytical validation, and clinical validation (V3): the foundation of determining fit-for-purpose for biometric monitoring technologies (BioMeTs). NPJ Digit Med. (2020) 3:55. 10.1038/s41746-020-0260-432337371
Jeon J Kwon S-Y Lee Y-M Hong J Yu J Kim J et al. Influence of the Hawthorne effect on spatiotemporal parameters, kinematics, ground reaction force, and the symmetry of the dominant and nondominant lower limbs during gait. J Biomech. (2023) 152. 10.1016/j.jbiomech.2023.111555
Boehme P Hansen A Roubenoff R Scheeren J Herrmann M Mondritzki T et al. How soon will digital endpoints become a cornerstone for future drug development? Drug Discov Today. (2019) 24:16–9. 10.1016/j.drudis.2018.07.00130009955
Lilien C Gasnier E Gidaro T Seferian A Grelet M Vissière D et al. Home-based monitor for gait and activity analysis. J Vis Exp. (2019). 10.3791/5966831449251
Servais L Camino E Clement A McDonald CM Lukawy J Lowes LP et al. First regulatory qualification of a novel digital endpoint in Duchenne muscular dystrophy: a multi-stakeholder perspective on the impact for patients and for drug development in neuromuscular diseases. Digit Biomark. (2021) 5:183–90. 10.1159/00051741134723071
Gidaro T Gasnier E Annoussamy M Vissing J Attarian S Mozaffar T et al. Home-based gait analysis as an exploratory endpoint during a multicenter phase 1 trial in limb girdle muscular dystrophy type R2 and facioscapulohumeral muscular dystrophy. Muscle Nerve. (2022) 65:237–42. 10.1002/mus.2744634687225
Kirk C Küderle A Micó-Amigo ME Bonci T Paraschiv-Ionescu A Ullrich M et al. Mobilise-D insights to estimate real-world walking speed in multiple conditions with a wearable device. Sci Rep. (2024) 14:1754. 10.1038/s41598-024-51766-538243008
Buekers J Chernova J Koch S Marchena J Lemos J Becker C et al. Digital assessment of real-world walking in people with impaired mobility: how many hours and days are needed? Int J Behav Nutr Phys Act. (2025) 22. 10.1186/s12966-025-01851-340001100